Many Cardiovascular Devices Approved by Process That Often Does Not Require New Clinical Data

Many Cardiovascular Devices Approved by Process That Often Does Not Require New Clinical Data

26 Jan 2014

Many cardiac implantable electronic device models currently in use were approved via a Food and Drug Administration review process in which the models were assumed safe and effective based on approval of prior versions of the device, according to a study in the January 22/29 issue of JAMA.

“In the United States, the Food and Drug Administration (FDA) reviews high-risk medical devices—those that support human life, prevent illness, or present an unreasonable risk—via the premarket approval (PMA) pathway, through which manufacturers collect preclinical and clinical data as necessary to provide ‘reasonable assurance’ of the device’s safety and effectiveness,” according to background information in the article. That process has attracted attention in recent years after recall of device components, like leads from Medtronic Sprint Fidelis and St. Jude Medical Riata implantable cardioverter-defibrillators (ICDs), that were not tested clinically in human trials prior to approval because they were design changes to prior-marketed devices and considered ‘supplements’ to PMA applications submitted almost a decade earlier.

The process of approval by premarket approval supplement “allow[s] patients to benefit from incremental innovation in device technology by providing efficient and inexpensive FDA review pathways for smaller device changes. Supplements may include major or minor design changes as well as routine changes in labeling, materials, or packaging. By statute, the FDA must seek only the ‘least burdensome’ supporting data necessary for review.”

Benjamin N. Rome, B.A., of Harvard Medical School and Brigham and Women’s Hospital, Boston, and colleagues used the FDA’s PMA database to review CIEDs (including pacemakers, ICDs, and cardiac resynchronization therapy [CRT] devices) approved as PMA supplements from 1979 through 2012. They identified the number of supplements to each original PMA and characterized the nature of the changes in each supplement.

Seventy-seven approved PMA applications for CIEDs (46 pacemaker devices, 19 ICDs, and 12 CRT devices) were the basis for 5,829 PMA supplement applications, with a median (midpoint) of 50 supplements per original PMA. In the last decade, the number of approved supplements annually increased to 704. Excluding manufacturing changes that do not alter device design, the number of supplements approved each year averaged 2.6 per PMA per year.

Thirty-seven percent of supplements represented at least minor alterations to the device’s design or materials. Among 180-day supplements (a type of FDA review process) approved between 2010 and 2012, 23 percent included new clinical data to support safety and effectiveness.

“… Our results should not be interpreted to indicate that the FDA is failing to review PMA supplement applications to determine safety and effectiveness,” the authors conclude. However, clinicians and patients should … be aware … that clinical data are rarely collected as part of PMA supplement applications prior to marketing. The recalled Medtronic Sprint Fidelis and St. Jude Riata ICD leads were both PMA supplements — Fidelis a 180-day supplement and Riata a real-time supplement [a type of FDA review process]. Neither lead was studied in human trials prior to FDA approval. The FDA’s approval of many supplements without new human trials, as in the case of these recent ICD changes, highlights the importance of collecting rigorous postapproval performance data,” the authors write.

(doi:10.1001/jama.2013.284986;

Dear Bankix Systems Readers, We’ll go straight to the point:
This is a fund-raising campaign.
We need your help to sustain our efforts and to remain online.
We want to keep writing the stories of the week for you free.
We want to keep providing all the other free services we offer.
Our goal is to enhance your mental and physical health.
We need your help to continue to be your go-to health media portal.
Your donations will help keep us online; every little helps.
Donate now. Thank you.

DISCLAIMER:Bankix Systems Ltd is the registered name of a Canadian firm since 2003, and bankixsystems.com is its OFFICIAL website. Besides these entities, we have no relationship with anyone, business, website, or any other entity anywhere in the world, claiming to be Bankix Systems, or using a similar name, and creating the impression that it has some connection with our company. We do not endorse and are therefore, not responsible for any act or lack thereof by any such entity. Bankix Systems Ltd is also not responsible for the content of the description of products and services linked to our site nor does it necessarily endorse them. The information here provided is not for diagnosing/treating your health concerns. Kindly contact your doctor or health care professional for all your healthcare requirements.